Advanced non-small cell lung cancer: Subsequent systemic therapy for previously treated patients
- Rogerio C Lilenbaum, MD, FACP
Rogerio C Lilenbaum, MD, FACP
- Section Editor — Lung Cancer
- Yale Cancer Center
Initial systemic therapy (chemotherapy or targeted agents) may delay disease progression and prolong survival in patients with advanced non-small cell lung cancer (NSCLC). However, almost all patients eventually develop progressive disease requiring further treatment.
Advances in the use of chemotherapy, targeted agents, and immunotherapy have led to the sequential use of multiple lines of therapy. The choice and sequence of subsequent therapies will be presented here.
The initial management of advanced NSCLC is presented separately. (See "Overview of the treatment of advanced non-small cell lung cancer".)
Further details regarding the rationale and data supporting the use of immunotherapy and targeted therapies are discussed elsewhere:To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:1836.
- Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 2014; 311:1430.
- Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095.
- Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43:183.
- Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354.
- Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:1377.
- Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91:1996.
- Tsalic M, Gilboa M, Visel B, et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol 2006; 23:57.
- Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.
- Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007; 2:397.
- Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14:253.
- Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665.
- Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83:447.
- Nokihara H, Lu S, Mok TS, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 2017.
- Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:4405.
- Nagano T, Kim YH, Goto K, et al. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. Lung Cancer 2010; 69:315.
- Socinski MA, Stinchcombe TE, Hayes DN, Morris DE. The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy. Semin Oncol 2006; 33:S32.
- Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014; 15:713.
- Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11:619.
- Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 2012; 30:3640.
- Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16:990.
- GOALS OF TREATMENT
- PRETREATMENT ASSESSMENT
- NO DRIVER MUTATION PRESENT
- Suggested sequence of therapies
- - Immunotherapy
- - Single-agent chemotherapy
- DRIVER MUTATION PRESENT
- SELECTION OF SINGLE-AGENT CHEMOTHERAPY
- Approach based on histology
- Efficacy and toxicities
- - Docetaxel
- - Pemetrexed
- - Ramucirumab plus docetaxel
- - Gemcitabine
- - S-1 oral fluoropyrimidine
- DURATION OF TREATMENT
- SPECIAL CONSIDERATIONS
- Older and medically complicated patients
- Retreatment after initial response
- Relapse after definitive therapy
- Local management of metastases
- PROMISING INVESTIGATIONAL STRATEGIES
- New inhibitors of molecular targets
- Proteomic signature assay
- THERAPIES TO BE AVOIDED
- Chemotherapy plus a tyrosine kinase inhibitor
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS